Oral Graft-Versus-Host Disease

Dental Clinics of North America

Volumn 58, Issue 2, 2014, Pages 351-368

  Kuten Shorrer, Michal ^a   Woo, Sook Bin ^b   Treister, Nathaniel S ^b  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Allogeneic; Graft versus host disease; GVHD; Hematopoietic cell transplantation; Oral mucosal disease

Indexed keywords

ADVERSE EFFECTS; ALLOGRAFT; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MOUTH DISEASES; QUALITY OF LIFE; TRANSPLANTATION;

ALLOGRAFTS; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MOUTH DISEASES; QUALITY OF LIFE; TRANSPLANTATION CONDITIONING;

EID: 84896328201     PISSN: 00118532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cden.2013.12.007     Document Type: Review

References (84)

1. Blazar B.R., Murphy W.J., Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012, 12(6):443-458.
2. Perez-Simon J.A., Sanchez-Abarca I., Diez-Campelo M., et al. Chronic graft-versus-host disease: pathogenesis and clinical management. Drugs 2006, 66(8):1041-1057.
3. Billingham R.E. The biology of graft-versus-host reactions. Harvey Lect 1966, 62:21-78.
4. Vogelsang G.B., Lee L., Bensen-Kennedy D.M. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 2003, 54:29-52.
5. Ferrara J.L., Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006, 43(1):3-10.
6. Pavletic S.Z., Fowler D.H. Are we making progress in GVHD prophylaxis and treatment?. Hematology Am Soc Hematol Educ Program 2012, 2012:251-264.
7. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110(13):4576-4583.
8. Spellman S.R., Eapen M., Logan B.R., et al. Aperspective on the selection of unrelated donors and cord blood units for transplantation. Blood 2012, 120(2):259-265.
9. Warren E.H., Zhang X.C., Li S., et al. Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood 2012, 120(14):2796-2806.
10. Weiden P.L., Sullivan K.M., Flournoy N., et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. NEngl J Med 1981, 304(25):1529-1533.
11. Schubert M.M., Correa M.E. Oral graft-versus-host disease. Dent Clin North Am 2008, 52(1):79-109. viii-ix.
12. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11(12):945-956.
13. Bolanos-Meade J., Vogelsang G.B. Acute graft-versus-host disease. Clin Adv Hematol Oncol 2004, 2(10):672-682.
14. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102(2):756-762.
15. Goker H., Haznedaroglu I.C., Chao N.J. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001, 29(3):259-277.
16. Deeg H.J., Antin J.H. The clinical spectrum of acute graft-versus-host disease. Semin Hematol 2006, 43(1):24-31.
17. Imanguli M.M., Alevizos I., Brown R., et al. Oral graft-versus-host disease. Oral Dis 2008, 14(5):396-412.
18. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15(6):825-828.
19. Dignan F.L., Clark A., Amrolia P., et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol 2012, 158(1):30-45.
20. Gratwohl A., Hermans J., Apperley J., et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood 1995, 86(2):813-818.
21. Kansu E. The pathophysiology of chronic graft-versus-host disease. Int J Hematol 2004, 79(3):209-215.
22. Kataoka Y., Iwasaki T., Kuroiwa T., et al. The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease. Immunology 2001, 103(3):310-318.
23. Shimabukuro-Vornhagen A., Hallek M.J., Storb R.F., et al. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009, 114(24):4919-4927.
24. Allen J.L., Fore M.S., Wooten J., et al. Bcells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood 2012, 120(12):2529-2536.
25. Kharfan-Dabaja M.A., Cutler C.S. Rituximab for prevention and treatment of graft-versus-host disease. Int J Hematol 2011, 93(5):578-585.
26. Shulman H.M., Sale G.E., Lerner K.G., et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978, 91(3):545-570.
27. Lee S.J., Vogelsang G., Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9(4):215-233.
28. Baird K., Pavletic S.Z. Chronic graft versus host disease. Curr Opin Hematol 2006, 13(6):426-435.
29. Kuzmina Z., Eder S., Bohm A., et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia 2012, 26(4):746-756.
30. Subramaniam D.S., Fowler D.H., Pavletic S.Z. Chronic graft-versus-host disease in the era of reduced-intensity conditioning. Leukemia 2007, 21(5):853-859.
31. Woo S.B., Lee S.J., Schubert M.M. Graft-vs-host disease. Crit Rev Oral Biol Med 1997, 8(2):201-216.
32. Treister N.S., Cook E.F., Antin J., et al. Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008, 14(1):110-115.
33. Treister N., Duncan C., Cutler C., et al. How we treat oral chronic graft-versus-host disease. Blood 2012, 120(17):3407-3418.
34. Mays J., Fassil H., Edwards D., et al. Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis 2012, 19(4):327-346.
35. Nagler R.M., Nagler A. Sialometrical and sialochemical analysis of patients with chronic graft-versus-host disease-a prolonged study. Cancer Invest 2003, 21(1):34-40.
36. Coracin F.L., Pizzigatti Correa M.E., Camargo E.E., et al. Major salivary gland damage in allogeneic hematopoietic progenitor cell transplantation assessed by scintigraphic methods. Bone Marrow Transplant 2006, 37(10):955-959.
37. Meier J.K., Wolff D., Pavletic S., et al. Oral chronic graft-versus-host disease: report from the International Consensus Conference on Clinical Practice in cGVHD. Clin Oral Investig 2011, 15(2):127-139.
38. Castellarin P., Stevenson K., Biasotto M., et al. Extensive dental caries in patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012, 18(10):1573-1579.
39. Pavletic S.Z., Lee S.J., Socie G., et al. Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transplant 2006, 38(10):645-651.
40. Shulman H.M., Kleiner D., Lee S.J., et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology working group report. Biol Blood Marrow Transplant 2006, 12(1):31-47.
41. Schubert M.M., Sullivan K.M., Morton T.H., et al. Oral manifestations of chronic graft-v-host disease. Arch Intern Med 1984, 144(8):1591-1595.
42. Soares A.B., Faria P.R., Magna L.A., et al. Chronic GVHD in minor salivary glands and oral mucosa: histopathological and immunohistochemical evaluation of 25 patients. JOral Pathol Med 2005, 34(6):368-373.
43. Sato M., Tokuda N., Fukumoto T., et al. Immunohistopathological study of the oral lichenoid lesions of chronic GVHD. JOral Pathol Med 2006, 35(1):33-36.
44. Socie G., Stone J.V., Wingard J.R., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. NEngl J Med 1999, 341(1):14-21.
45. Pidala J. Graft-vs-host disease following allogeneic hematopoietic cell transplantation. Cancer Control 2011, 18(4):268-276.
46. Fraser C.J., Bhatia S., Ness K., et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 2006, 108(8):2867-2873.
47. Lee S.J., Klein J.P., Barrett A.J., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002, 100(2):406-414.
48. Lee S.J., Kim H.T., Ho V.T., et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 2006, 38(4):305-310.
49. Fall-Dickson J.M., Mitchell S.A., Marden S., et al. Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16(7):948-956.
50. Hull K.M., Kerridge I., Schifter M. Long-term oral complications of allogeneic haematopoietic SCT. Bone Marrow Transplant 2012, 47(2):265-270.
51. Imanguli M.M., Atkinson J.C., Mitchell S.A., et al. Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation. Biol Blood Marrow Transplant 2010, 16(10):1362-1369.
52. Fassil H., Bassim C.W., Mays J., et al. Oral chronic graft-vs-host disease characterization using the NIH scale. JDent Res 2012, 91(Suppl 7):45S-51S.
53. Treister N., Chai X., Kurland B., et al. Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium. Bone Marrow Transplant 2013, 48(8):1123-1128.
54. Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol 2007, 137(2):87-98.
55. Bolanos-Meade J. Update on the management of acute graft-versus-host disease. Curr Opin Oncol 2006, 18(2):120-125.
56. Lee S.J., Flowers M.E. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008, 134-141.
57. Perkins J., Field T., Kim J., et al. Arandomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010, 16(7):937-947.
58. Cutler C., Kim H.T., Hochberg E., et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004, 10(5):328-336.
59. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109(7):3108-3114.
60. Dignan F.L., Amrolia P., Clark A., et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol 2012, 158(1):46-61.
61. Cutler C., Antin J.H. Chronic graft-versus-host disease. Curr Opin Oncol 2006, 18(2):126-131.
62. Wolff D., Schleuning M., von Harsdorf S., et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011, 17(1):1-17.
63. Wolff D., Gerbitz A., Ayuk F., et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010, 16(12):1611-1628.
64. Koc S., Leisenring W., Flowers M.E., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002, 100(1):48-51.
65. Arora M., Burns L.J., Davies S.M., et al. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant 2003, 9(1):38-45.
66. Stewart B.L., Storer B., Storek J., et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004, 104(12):3501-3506.
67. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006, 12(4):375-396.
68. Mawardi H., Stevenson K., Gokani B., et al. Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD. Bone Marrow Transplant 2010, 45(6):1062-1067.
69. Fox P.C. Salivary enhancement therapies. Caries Res 2004, 38(3):241-246.
70. Nagler R.M., Nagler A. The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease. Arch Oral Biol 2001, 46(8):689-695.
71. Carpenter P.A., Schubert M.M., Flowers M.E. Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease. Biol Blood Marrow Transplant 2006, 12(7):792-794.
72. Chainani-Wu N., Gorsky M., Mayer P., et al. Assessment of the use of sialogogues in the clinical management of patients with xerostomia. Spec Care Dentist 2006, 26(4):164-170.
73. Elad S., Garfunkel A.A., Enk C.D., et al. Ultraviolet B irradiation: a new therapeutic concept for the management of oral manifestations of graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999, 88(4):444-450.
74. Menillo S.A., Goldberg S.L., McKiernan P., et al. Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-versus-host disease following allogeneic stem cell transplantation. Bone Marrow Transplant 2001, 28(8):807-808.
75. Elad S., Or R., Shapira M.Y., et al. CO2 laser in oral graft-versus-host disease: a pilot study. Bone Marrow Transplant 2003, 32(10):1031-1034.
76. Wolff D., Anders V., Corio R., et al. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease. Photodermatol Photoimmunol Photomed 2004, 20(4):184-190.
77. Chor A., de Azevedo A.M., Maiolino A., et al. Successful treatment of oral lesions of chronic lichenoid graft-vs-host disease by the addition of low-level laser therapy to systemic immunosuppression. Eur J Haematol 2004, 72(3):222-224.
78. Rizzo J.D., Wingard J.R., Tichelli A., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006, 12(2):138-151.
79. Hasegawa W., Pond G.R., Rifkind J.T., et al. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant 2005, 35(1):51-55.
80. Demarosi F., Lodi G., Carrassi A., et al. Oral malignancies following HSCT: graft versus host disease and other risk factors. Oral Oncol 2005, 41(9):865-877.
81. Majhail N.S. Secondary cancers following allogeneic haematopoietic cell transplantation in adults. Br J Haematol 2011, 154(3):301-310.
82. Socie G., Rizzo J.D. Second solid tumors: screening and management guidelines in long-term survivors after allogeneic stem cell transplantation. Semin Hematol 2012, 49(1):4-9.
83. Curtis R.E., Metayer C., Rizzo J.D., et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005, 105(10):3802-3811.
84. Mawardi H., Elad S., Correa M.E., et al. Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant 2011, 46(6):884-891.